Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • Bitcoin USD

    64,506.14
    +919.07 (+1.45%)
     

  • CMC Crypto 200

    1,388.11
    +75.48 (+6.11%)
     

  • S&P 500

    4,987.63
    -23.49 (-0.47%)
     

  • Dow

    37,952.08
    +176.70 (+0.47%)
     

  • Nasdaq

    15,400.28
    -201.22 (-1.29%)
     

  • Gold

    2,408.90
    +10.90 (+0.45%)
     

  • Crude Oil

    83.10
    +0.37 (+0.45%)
     

  • 10-Yr Bond

    4.6060
    -0.0410 (-0.88%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Lilly Gets FDA Approval for New Oral Tablets for Migraine

Zacks Equity Research

Eli Lilly & Company LLY announced that the FDA has approved lasmiditan for the treatment of acute migraine headaches, with or without aura, in adults. Lasmiditan, an oral 5-HT1F agonist, is the first and only FDA-approved medicine in this class of migraine drugs. Lasmiditan will be marketed by the trade name of Reyvow and will be available in oral doses of 50 mg, 100 mg, and 200 mg, once launched.

The new drug application for Reyvow was based on data from two phase III studies, SAMURAI and SPARTAN. Both the studies met the efficacy endpoints. Data from the studies showed that treatment with Reyvow led to pain freedom and freedom from most bothersome symptoms of migraine at two hours after administration of Reyvow compared to placebo.

Please note that lasmiditan was added to Lilly’s portfolio with the 2017 acquisition of CoLucid Pharmaceuticals.

Year to date, Lilly’s shares have declined 6.3% compared with the industry’s decrease of 0.8%.

ADVERTISEMENT

 

 

Reyvow’s approval has boosted Lilly’s portfolio of pain medicines, which also includes recently launched, Emgality, its CGRP antibody, for the preventive treatment of migraine.  Emgality was launched in the United States in September last year. Emgality was approved in the United States for another indication, episodic cluster headache in June 2019. Emgality, a once-monthly, self-administered, subcutaneous 120 mg injection, could emerge as a significant contributor to long-term growth at Lilly. However, it faces strong competition from Teva TEVA and Amgen’s AMGN CGRPs, Ajovy and Aimovig, respectively, which were also approved in 2018.

Lilly’s pain portfolio also includes tanezumab, which is being evaluated, in collaboration with Pfizer, Inc. PFE. Lilly expects to file a NDA for tanezumab for treating osteoarthritis pain next year.

Lilly currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Eli Lilly and Company (LLY) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research